Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

B-cell Lymphoma Clinical Trial

Official title:

Study to Evaluate the Efficacy and Safety of Relmacabtagene Autoleucel (Relma-cel) as First-Line Therapy in Adult Participants With High-Risk Large B-Cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05590221
• Other study ID #: JWCAR029011
• Status: Recruiting
• Phase: Phase 2
• Start date: January 3, 2023
• Est. completion date: December 10, 2024

Study information

• Verified date: November 2023
• Source: Peking University Cancer Hospital & Institute
• Contact: Yuqin Song, PhD
• Phone: +86 010-88121122
• Email: songyuqin622[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to estimate the efficacy of Relmacabtagene Autoleucel in participants with high-risk large B-cell lymphoma.

Description:

This is a prospective, open-label, multicenter, single-arm trial, assessed the efficacy and safety of JWCAR029(relma-cel) as part of first-line therapy after an incomplete first-line treatment regimen of two cycles of chemoimmunotherapy. High-risk LBCL was defined by the dynamic risk assessment of interim PET2+, together with either double- or triple-hit lymphomas or high-intermediate- and high-risk IPI scores (≥3). All sujects will be followed for 2 years following JWCAR029 infusion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 10, 2024
• Est. primary completion date: February 10, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. = 18 years old;

2. Sign on the informed consent;

3. Histologically confirmed large B-cell lymphoma that also meets the definition of high-risk large B-cell lymphoma as a lymphoma International Prognostic Index (IPI) score of 3-5 and/or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement (double/triple-hit lymphoma) (DHL/THL) and must be treated with 2 cycles of CD20 monoclonal antibodies combined with anthracyclines. Presence of positive PET assessable lesions (DS score of 4 or 5) as determined by the Lugano criteria (Cheson et al., 2014);

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

5. Expected survival greater than 12 weeks;

6. Adequate organ function:

1. Absolute neutrophil count = 1000/µL;Absolute lymphocyte count = 100/µL; Platelet count = 75,000/µL;Hb = 80g/L;

2. Serum creatinine = 1.5 × upper limit of normal (ULN) or creatinine clearance (Cockcroft-Gault formula) > 50 mL/min (serum creatinine clearance due to lymphoma mass compression should be > 30 mL/min);

3. Serum alanine aminotransferase (ALT) = 5 upper limit of normal (ULN) and total bilirubin =2ULN(or for subjects with Gilbert's syndrome or lymphoma invading the liver < 3 ULN);

4. Baseline oxygen saturation > 92% on room air;

5. Left ventricular ejection fraction (LVEF) =50% assessed by echocardiography or radionuclide activity angiography (MUGA) within 1 month of enrollment;

7. Adequate vascular access for leukapheresis procedure;

8. Women of childbearing potential must agree to use highly effective methods of contraception for at least 28 days prior to lymphocyte clearance chemotherapy through 1 year after Relmacabtagene Autoleucel infusion; Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for 1 year after Relmacabtagene Autoleucel infusion.

Exclusion Criteria:

1. Lymphoma involving the central nervous system (CNS);

2. History of another primary malignancy that has not been in remission for at least 2 years;

3. History of Richter's transformation of chronic lymphocytic leukemia or primary mediastinal B-cell lymphoma;

4. Subjects has HBV, HCV, HIV or syphilis infection at the time of screening;

5. Deep venous thrombosis (DVT)/Pulmonary embolism (PE), or DVT/PE requires anti-coagulation within 3 months prior to signing the ICF;

6. Subjects with uncontrolled systemic fungal, bacterial, viral or other infection;

7. Presence of acute or chronic graft-versus-host disease (GVHD);

8. History of any serious cardiovascular disease or presence of clinically relevant CNS pathology;

9. Pregnant or nursing women;

10. Subjects Received an autologous or allogeneic hematopoietic stem cell transplant;

11. Uncontrolled conditions or unwillingness or inability to follow the procedures required in the protocol;

12. Received CAR T-cell or other genetically-modified T-cell therapy previously;

13. Received live vaccination within 6 weeks prior to lymphocyte clearance chemotherapy;

14. History of severe hypersensitivity reactions to any of the drug ingredients used in this study product.

Related Conditions & MeSH terms

• B-cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell

Intervention

Biological:
• Relmacabtagene Autoleucel
A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Drug:
• Fludarabine
Administered according to package insert
• Cyclophosphamide
Administered according to package insert

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing
China	Peking University International Hospital	Beijing	Beijing
China	Tianjin Medical University Cancer Institute and Hospital	Tianjin	Tianjin
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
Peking University Cancer Hospital & Institute	Shanghai Ming Ju Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Response (CR) Rate Per the Lugano Classification as Determined by Study Investigators	Complete Response Rate (CRR): percentage of participants with CR [complete metabolic response (CMR); complete radiological response (CRR)]. CMR: positron emission tomography (PET) 5-point scale (5-PS) scores of 1 (no uptake above background), 2 (uptake = mediastinum), 3 (uptake > mediastinum but = liver) with/without a residual mass); no new lesions; and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow (BM). CRR: target nodes/nodal masses regressed to = 1.5 cm in longest transverse diameter of lesion (LDi); no extralymphatic sites of disease; absent non-measured lesion (NMLs); organ enlargement regress to normal; no new sites; and bone marrow normal by morphology.	up to 2 years after Relmacabtagene Autoleucel infusion
Secondary	Objective Response Rate (ORR) Per the Lugano Classification as Determined by Study Investigators	ORR: percentage of participants with CR [CMR;CRR] or PR [partial metabolic response (PMR); partial radiologic response (PRR)].CMR: PET 5PS scores of 1 (no uptake above background, 2 (uptake = mediastinum), 3 (uptake > mediastinum but = liver) with/without a residual mass; no new lesions; no evidence of FDG-avid disease in BM. CRR:target nodes/nodal masses regressed to = 1.5 cm in LDi;no extralymphatic sites of disease;absent NMLs;organ enlargement regress to normal;no new sites;bone marrow morphology normal. PMR:scores 4 (uptake moderately > liver),5 (uptake markedly > liver, new lesions) with reduced uptake compared with baseline and residual mass;no new lesions;responding disease at interim/residual disease at end of treatment (EOT).PRR: = 50% decrease in sum of the product of perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites;absent/normal, regressed, but no increase of NMLs;spleen regressed by > 50% in length beyond normal;no new sites.	up to 2 years after Relmacabtagene Autoleucel infusion
Secondary	Duration of Response (DOR) Per the Lugano Classification	DOR is defined only for participants who experience an objective response after Relmacabtagene Autoleucel infusion and is the time from the first objective response to disease progression or death from any cause. Objective response is defined in outcome measure (OM) 2.	up to 2 years after Relmacabtagene Autoleucel infusion
Secondary	Event-Free Survival (EFS)	First infusion date of Relmacabtagene Autoleucel to data cut off	up to 2 years after Relmacabtagene Autoleucel infusion
Secondary	Progression-Free Survival (PFS)	PFS is defined as the time from the Relmacabtagene Autoleucel infusion date to the date of disease progression per Lugano classification or death from any cause.	up to 2 years after Relmacabtagene Autoleucel infusion
Secondary	Overall Survival (OS)	OS is defined as the time from Relmacabtagene Autoleucel infusion to the date of death from any cause.	up to 2 years after Relmacabtagene Autoleucel infusion
Secondary	Types, frequency, and severity of adverse events and laboratory anomalies	Physiological parameter	up to 2 years after Relmacabtagene Autoleucel infusion
Secondary	Pharmacokinetic (PK)- Cmax of Relmacabtagene Autoleucel	Maximum observed concentration of Relmacabtagene Autoleucel in peripheral blood	up to 1 year after Relmacabtagene Autoleucel infusion
Secondary	Pharmacokinetic (PK)- Tmax of Relmacabtagene Autoleucel	Time to maximum concentration of Relmacabtagene Autoleucel in peripheral blood	up to 1 year after Relmacabtagene Autoleucel infusion
Secondary	Pharmacokinetic (PK)- AUC of Relmacabtagene Autoleucel	Area under the concentration vs time curve of Relmacabtagene Autoleucel	up to 1 year after Relmacabtagene Autoleucel infusion
Secondary	The concentration of Car-T cell	The concentration of Car-T cell in peripheral blood	up to 1 year after Relmacabtagene Autoleucel infusion
Secondary	The change of serum cytokines concentration	The change of serum cytokines(IL-2?IL-4?IL-6?IL-8?IL-10?IL-17A?IFN-??TNF-a?IFN-a) concentration after Relmacabtagene Autoleucel infusion	up to 1 year after Relmacabtagene Autoleucel infusion